These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18537662)

  • 1. Cyclooxygenases and cyclooxygenase inhibitors in neurological and psychiatric diseases.
    Minghetti L
    Curr Pharm Des; 2008; 14(14):1400. PubMed ID: 18537662
    [No Abstract]   [Full Text] [Related]  

  • 2. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.
    Choi SH; Aid S; Bosetti F
    Trends Pharmacol Sci; 2009 Apr; 30(4):174-81. PubMed ID: 19269697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement therapy for the treatment of neurological and neuropsychiatric disorders.
    Gold SM; Voskuhl RR
    Curr Opin Investig Drugs; 2006 Jul; 7(7):625-30. PubMed ID: 16869115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Fischer A
    Drug Res (Stuttg); 2017 Nov; 67(S 01):S9. PubMed ID: 29069674
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise?
    Pruthi RS; Kouba E; Carson CC; Wallen EM
    Urology; 2006 Nov; 68(5):917-23. PubMed ID: 17113880
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclooxygenase-2 inhibitors and prostate cancer.
    James N
    Lancet Oncol; 2007 Oct; 8(10):859-60. PubMed ID: 17913653
    [No Abstract]   [Full Text] [Related]  

  • 7. Challenges in developing drugs for neurological and psychiatric disorders.
    Simon NG; Brownstein MJ
    Prog Neurobiol; 2017 May; 152():1-2. PubMed ID: 28442128
    [No Abstract]   [Full Text] [Related]  

  • 8. From genes to effective drugs for neurological and psychiatric diseases.
    Hefti F
    Trends Pharmacol Sci; 2001 Apr; 22(4):159-60. PubMed ID: 11282404
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-inflammatory drugs in psychiatry.
    Berthold-Losleben M; Heitmann S; Himmerich H
    Inflamm Allergy Drug Targets; 2009 Sep; 8(4):266-76. PubMed ID: 19754410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
    Wang ZZ; Zhang Y; Zhang HT; Li YF
    Curr Pharm Des; 2015; 21(3):303-16. PubMed ID: 25159069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease.
    Noguchi K; Ishikawa I
    Periodontol 2000; 2007; 43():85-101. PubMed ID: 17214837
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclooxygenase-2 in transitional cell carcinoma--a legitimate target?
    Adam R
    J Urol; 2007 Mar; 177(3):818-9. PubMed ID: 17296349
    [No Abstract]   [Full Text] [Related]  

  • 13. Complex roles of cyclo-oxygenase 2 in hepatitis.
    Holt AP; Adams DH
    Gut; 2007 Jul; 56(7):903-4. PubMed ID: 17566025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 in cardiovascular disease.
    Bishop-Bailey D; Mitchell JA; Warner TD
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):956-8. PubMed ID: 16627818
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice.
    Girgis H; Palmier B; Croci N; Soustrat M; Plotkine M; Marchand-Leroux C
    Brain Res; 2013 Jan; 1491():78-87. PubMed ID: 23122881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On the origin and the activity of ornithine-carbamoyltransferase in cerebrospinal fluid in neurological-psychiatric diseases].
    Kluge H; Wieczorek V; Unger F; Greger J
    Psychiatr Neurol (Basel); 1967; 154(2):88-94. PubMed ID: 6053460
    [No Abstract]   [Full Text] [Related]  

  • 17. Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
    Ye N; Neumeyer JL; Baldessarini RJ; Zhen X; Zhang A
    Chem Rev; 2013 May; 113(5):PR123-78. PubMed ID: 23464812
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting voltage-gated calcium channels in neurological and psychiatric diseases.
    Zamponi GW
    Nat Rev Drug Discov; 2016 Jan; 15(1):19-34. PubMed ID: 26542451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroscience. The dark side of glia.
    Miller G
    Science; 2005 May; 308(5723):778-81. PubMed ID: 15879185
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.